A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting

Background: Therapy resistance remains a serious dilemma in metastatic castration-resistant prostate cancer (mCRPC) with primary or secondary resistance frequently occurring against any given therapy. Available prognostic models for Abiraterone Acetate (AA) are specifically designed for either pre-...

Descripción completa

Detalles Bibliográficos
Autores principales: Boegemann, Martin, Schlack, Katrin, Früchtenicht, Lena, Steinestel, Julie, Schrader, Andres Jan, Wennmann, Yvonne, Krabbe, Laura-Maria, Eminaga, Okyaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707939/
https://www.ncbi.nlm.nih.gov/pubmed/31489117
http://dx.doi.org/10.18632/oncotarget.27133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707939/
https://www.ncbi.nlm.nih.gov/pubmed/31489117
http://dx.doi.org/10.18632/oncotarget.27133

Ejemplares similares